Free tool
FAERS Monitor: Ultiva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020630 or its brand name (Ultiva, Remifentanil Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,419
Serious
2,326
96% of reports
Hospitalization
920
Death reported
247
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic shock370
- hypotension166
- anaphylactic reaction151
- cardiac arrest122
- blood pressure decreased105
- bradycardia88
- tachycardia87
- bronchospasm78
- rash72
- erythema63
- toxic epidermal necrolysis62
- drug ineffective59
- oxygen saturation decreased58
- drug interaction56
- off label use54
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 26 |
| 2005 | 41 |
| 2006 | 24 |
| 2007 | 43 |
| 2008 | 67 |
| 2009 | 80 |
| 2010 | 104 |
| 2011 | 90 |
| 2012 | 128 |
| 2013 | 166 |
| 2014 | 129 |
| 2015 | 109 |
| 2016 | 144 |
| 2017 | 95 |
| 2018 | 155 |
| 2019 | 125 |
| 2020 | 111 |
| 2021 | 98 |
| 2022 | 151 |
| 2023 | 149 |
| 2024 | 126 |
| 2025 | 131 |
| 2026 | 126 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 370 | 126.6 | 115.2 | 45,383 |
| bronchospasmSignal | 78 | 47.8 | 38.4 | 3,509 |
| toxic epidermal necrolysisSignal | 62 | 35.6 | 27.9 | 2,046 |
| anaphylactic reactionSignal | 151 | 23.8 | 20.4 | 3,279 |
| bradycardiaSignal | 88 | 14.5 | 11.8 | 1,090 |
| blood pressure decreasedSignal | 105 | 13.8 | 11.4 | 1,232 |
| cardiac arrestSignal | 122 | 12.9 | 10.8 | 1,326 |
| oxygen saturation decreasedSignal | 58 | 9.0 | 7.0 | 404 |
| tachycardiaSignal | 87 | 8.5 | 6.9 | 572 |
| hypotensionSignal | 166 | 7.2 | 6.2 | 888 |
| drug interactionSignal | 56 | 3.1 | 2.4 | 77 |
| erythemaSignal | 63 | 2.7 | 2.1 | 65 |
| rash | 72 | 1.4 | 1.1 | 9 |
| off label use | 54 | 0.5 | 0.4 | 22 |
| drug ineffective | 59 | 0.4 | 0.3 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.